Join the Mounjaro group to help and get support from people like you.
Mounjaro News (Page 3)
Biden Will Move to Have Medicare, Medicaid Cover GLP-1 Weight-Loss Meds, such as Wegovy, Zepbound
TUESDAY, Nov. 26, 2024 – The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and...
Taking a GLP-1 Medication? Here's Tips to Holiday Eating
SATURDAY, Nov. 23, 2024 – So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays near you worry about how to handle gatherings where...
Meds Like Ozempic Are Causing Folks to Waste More Food
FRIDAY, Nov. 22, 2024 – America's kitchen trash bins are receiving more unwanted food as appetites falter among people taking GLP-1 weight-loss meds, a new study shows. GLP-1s like Ozempic, Wegovy,...
AHA: Tirzepatide Beneficial for Heart Failure With Preserved EF, Obesity
FRIDAY, Nov. 22, 2024 – For patients with heart failure with preserved ejection fraction, tirzepatide yields a reduced risk for a composite of death from cardiovascular causes or worsening heart...
Tirzepatide Yields Sustained Weight Reduction in Obesity, Prediabetes
MONDAY, Nov. 18, 2024 – For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes,...
Diabetes Meds Metformin, GLP-1s Can Also Curb Asthma
MONDAY, Nov. 18, 2024 – Drugs already taken by millions of diabetes patients appear to also help slash asthma attacks by up to 70%, new British research shows. The two drugs are metformin, one of...
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
TUESDAY, Nov. 12, 2024 – For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced...
Expanding Access to Obesity Medications Could Avert 42,000 Deaths/Year
THURSDAY, Nov. 7, 2024 – Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could...
Most Patients Can Keep Using GLP-1 Weight Loss Meds Before Surgeries
THURSDAY, Oct. 31, 2024 – A new guidance issued jointly by groups representing U.S. surgeons, anesthesiologists and gastroenterologists affirms that most people taking popular GLP-1 weight-loss meds...
Weight-Loss Surgeries Decline 25% as More Americans Turn to GLP-1 Meds
FRIDAY, Oct. 25, 2024 – As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds....
FDA Medwatch Alert: FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
October 2, 2024 -- The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection ...
Weight-Loss Meds Like Wegovy, Ozempic Could Battle Alcoholism
THURSDAY, Oct. 17, 2024 – Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds. People taking...
Risk for Suicidal Ideation, Attempts Down With GLP1-RA Treatment in Teens With Obesity
TUESDAY, Oct. 15, 2024 – For adolescents with obesity, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is associated with a reduced risk for suicidal ideation or attempts, according to...
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now
TUESDAY, Oct. 15, 2024 – Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to...
GLP-1 Weight-Loss Meds, Wegovy, Zepbound, Won't Raise Teens' Suicide Risk, May Even Lower It
MONDAY, Oct. 14, 2024 – As with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might raise psychiatric risks, including the risk for suicide...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Diabetes, Type 2